Vanda Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Vanda Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Vanda Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Vanda Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Vanda Pharmaceuticals Inc (Vanda) is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; Ponvory for the treatment of relapsing forms of multiple sclerosis; Nereus for the treatment of patients with gastroparesis; and Fanapt, a typical antipsychotic for the treatment of schizophrenia in adults. The company’s major pipeline products include Tradipitant (VLY-686), VTR-297, VQW-765, CFTR, and a portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. The company targets markets in the US, Canada, and Europe. Vanda is headquartered in Washington D.C., the US.
Headquarters
United States of America
Address
Suite 300e, 2200 Pennsylvania Ave Nw, Washington, WashingtonD.C., 20037
Website
www.vandapharma.com
Telephone
1 202 7343400
No of Employees
533
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VNDA (NASD)
Revenue (2024)
$216.1M
8.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-1066.5%
(2024 vs 2023)
Market Cap*
$321.7M
Net Profit Margin (2024)
XYZ
-972.8%
(2024 vs 2023)
* As of and is in US$
Vanda Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Hetlioz (tasimelteon) - Non-24-Hour Sleep-Wake Disorder | Fanapt |
| Fanapt (iloperidone) - Schizophrenia | Hetlioz |
| Ponvory - Multiple Sclerosis | Ponvory |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In February, the company announced the approval of Bysanti (milsaperidone) for the treatment of bipolar I disorder and schizophrenia. |
| 2025 | Regulatory Approval | In December, the company announced FDA Approval of Nereus (tradipitant) for the prevention of vomiting induced by motion. |
| 2025 | Contracts/Agreements | In February, the company entered into a contract with AnaptysBio for the development and commercialization of imsidolimab. |
Competitor Comparison
| Key Parameters | Vanda Pharmaceuticals Inc | Johnson & Johnson | Roche Holding AG | Merck & Co Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United Kingdom |
| City | Washington | New Brunswick | Basel | Rahway | Cambridge |
| State/Province | WashingtonD.C. | New Jersey | Basel-Stadt | New Jersey | Cambridgeshire |
| No. of Employees | 533 | 138,200 | 112,774 | 75,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mihael H. Polymeropoulos, MD | President; Chairman; Chief Executive Officer | Executive Board | 2021 | 66 |
| Kevin Moran | Treasurer; Senior Vice President; Chief Financial Officer | Senior Management | 2020 | 42 |
| Joakim Wijkstrom | Senior Vice President; Chief Marketing Officer | Senior Management | 2019 | 60 |
| Scott Howell | Chief People Officer | Senior Management | 2019 | - |
| Deepak Phadke, Ph.D. | Vice President - Manufacturing | Senior Management | 2005 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer